RECENT NEWS

Uptake Medical Announces Successful Completion of Patient Enrollment in Pilot
Safety & Feasibility Clinical Trial for Patients with Heterogeneous Emphysema

Seattle, Washington – May 16, 2008. Uptake Medical announced today that it has completed patient enrollment in a phase I safety and feasibility clinical trial for the company's proprietary minimally invasive Bronchoscopic Thermal Vapor Ablation™ (BTVA™) treatment for patients suffering from heterogeneous emphysema with upper lobe predominance.

The trial was conducted at two centers in Australia with world renowned thoracic physicians, Dr. Gregory Snell of The Alfred Hospital, Melbourne, Victoria and Dr. Peter Hopkins of Prince Charles Hospital, Brisbane, Queensland from December 2007 to March 2008.

"We are pleased with the early data on the use of vapor therapy which demonstrates an acceptable safety profile and encouraging potential for efficacy. BTVA holds the promise of a safe, simple and elective bronchoscopic approach to lung volume reduction for many patients suffering from emphysema who have limited treatment options," said Dr. Gregory Snell.

"The early clinical results look very promising. The support and leadership of Dr. Snell and Dr. Hopkins have enabled Uptake Medical to conduct a very thorough Phase I Study in Australia and we look forward to building on this experience in the coming months throughout the world," noted King Nelson, President and CEO.

Bronchoscopic Thermal Vapor Ablation (BTVA) is a minimally-invasive procedure that helps patients with emphysema breathe more easily. BTVA achieves lung volume reduction by delivering thermal vapor through a catheter which causes the diseased portion of the lung to reduce in volume. This non-surgical lung volume reduction allows the remaining healthy lung to expand more fully and function more normally.

"Based on these positive initial results, we are eager to gain more clinical experience and move towards providing a viable non-surgical treatment to improve the lives of patients suffering from emphysema," said King Nelson, President and CEO.

Based on these encouraging results, Uptake Medical is planning to conduct further clinical trials in Europe, Australia and the US.

About Uptake Medical
Uptake Medical™ Corporation is a developer of medical technologies for the treatment of lung diseases including emphysema. The core technology is a simple, minimally invasive, non-implant interventional pulmonary approach designed to measurably improve lung function and patient quality of life. Emphysema afflicts over 3 million people in the United States.

Uptake Medical is a privately held company with investors that include: Prism Venture Partners, GBS Venture Partners, Onset Ventures, Affinity Capital, WRF Capital and Arboretum Ventures.

< Back

About Uptake Medical Corporation
Uptake Medical, headquartered in Seattle, Washington is a privately funded medical device company developing a bronchoscopic treatment for emphysema utilizing a unique thermal vapor ablation technology.
Read more >